Brokerages set Guardant Health, Inc. (NASDAQ:GH) PT at $39.00

Shares of Guardant Health, Inc. (NASDAQ:GH – Get Your Free Report ) has been given a consensus rating of “Moderate Buy” by the seventeen research firms that are presently covering the firm, MarketBeat Ratings reports. One analyst has rated the stock with a hold rating and sixteen have given a buy rating to the company. The average 1-year target price among analysts that have issued a report on the stock in the last year is $39.27.

Several equities analysts have weighed in on GH shares. Craig Hallum lifted their price target on Guardant Health from $28.00 to $37.00 and gave the company a “buy” rating in a research note on Thursday, August 8th. JPMorgan Chase & Co. boosted their price objective on shares of Guardant Health from $45.00 to $48.00 and gave the company an “overweight” rating in a research note on Thursday, August 8th. TD Cowen lifted their price target on shares of Guardant Health from $41.00 to $42.00 and gave the company a “buy” rating in a research note on Thursday, August 8th. BTIG Research upped their target price on shares of Guardant Health from $45.00 to $50.00 and gave the company a “buy” rating in a report on Tuesday, July 30th. Finally, Bank of America boosted their price objective on Guardant Health from $28.00 to $40.00 and gave the stock a “buy” rating in a report on Thursday, July 18th.

Read the latest stock analysis on Guardant Health

Institutional Trade of Guardant Health

Hedge funds have recently modified their holdings of the company. Manchester Capital Management LLC purchased a new position in shares of Guardant Health in the first quarter valued at $57,000. Canton Hathaway LLC bought a new position in Guardant Health in the second quarter valued at approximately $59,000. Headlands Technologies LLC boosted its holdings in Guardant Health by 362.3% during the fourth quarter. Headlands Technologies LLC now owns 2,353 shares of the company’s stock valued at $64,000 after buying an additional 1,844 shares during the last quarter. Point72 Asia Singapore Pte. Ltd. purchased a new stake in Guardant Health in the second quarter valued at approximately $71,000. Finally, Van ECK Associates Corp boosted its holdings in shares of Guardant Health by 29.4% in the 4th quarter. Van ECK Associates Corp now owns 2,702 shares of the company’s stock worth $73,000 after buying an additional 614 shares during the last quarter. Institutional investors own 92.60% of the company’s shares.

Guardant Health stock performance

Shares of NASDAQ GH opened at $28.54 on Tuesday. The stock’s fifty-day simple moving average is $30.63, and its 200-day simple moving average is $24.21. The stock has a market cap of $3.49 billion, a price-to-earnings ratio of -7.28 and a beta of 1.13. The company has a quick ratio of 5.66, a current ratio of 5.95, and a debt-to-equity ratio of 16.70. Guardant Health has a 52-week low of $15.81 and a 52-week high of $41.06.

Guardant Health (NASDAQ:GH – Get Free Report ) last issued its quarterly earnings data on Wednesday, August 7th. The company reported ($0.84) EPS for the quarter, missing analysts’ consensus estimates of ($0.74) by ($0.10). Guardant Health had a negative net margin of 76.34% and a negative return on equity of 246.47%. The firm had revenue of $177.24 million for the quarter, compared to analysts’ expectations of $162.59 million. In the same period last year, the company posted ($0.67) earnings per share. Guardant Health’s quarterly revenue was up 29.2% compared to the same quarter last year. As a group, sell-side analysts forecast that Guardant Health will post -3.31 earnings per share for the current fiscal year.

Guardant Health Company Profile

(Get a free report

Guardant Health, Inc, a precision oncology company, provides blood and tissue tests, datasets and analytics in the United States and internationally. The Company provides Guardant360; Guardant360 LDT; Guardant360 CDx test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with actionable modification tests with potentially relevant clinical trials; GuardantOMNI Test for advanced cancer; and GuardantINFORM, an in-silico research platform for biomarker-based tumor evolution and treatment resistance in various cancers.

Featured stories

Get news and reviews for Guardant Health Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Guardant Health and related companies with MarketBeat.com’s FREE daily email newsletter.